L-Isoleucin-ethylester | 921-74-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Isoleucin-ethylester
• 英文别名: L-isoleucine ethyl ester；Ethyl L-isoleucinate；ethyl (2S)-2-amino-3-methylpentanoate
• CAS: 921-74-4；97955-73-2
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: ICPWNTVICOHCML-MLWJPKLSSA-N

物化性质

• 沸点：
  75-76 °C(Press: 10 Torr)
• 密度：
  0.944±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  五氟丙硫酸乙酯 、 L-Isoleucin-ethylester 以93%的产率得到
  参考文献：
  名称：

  KAWA HAJIMU; ISHIKAWA NOBUO, J. FLUOR. CHEM., 1980, 16, NO 4, 365-372

  摘要：

  DOI：

文献信息

• [EN] CRYSTALLINE SALT OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-ISOLEUCINE ETHYL ESTER<br/>[FR] SEL CRISTALLIN D'ACIDE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLIQUE ET D'ESTER ÉTHYLIQUE DE L-ISOLEUCINE
  申请人：MERCK PATENT GMBH

  公开号：WO2020007836A1

  公开（公告）日：2020-01-09

  The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

  本发明涉及5-甲基-(6S)-四氢叶酸和L-异亮氨酸乙酯的结晶盐，其中5-甲基-(6S)-四氢叶酸和L-异亮氨酸乙酯的摩尔比为1：0.3至1：2.0（摩尔比）和/或其水合物和/或溶剂化物，以及其制备方法。
• COMPOSITION FOR USE IN PREVENTION OF HYPOGLYCEMIC CONDITION
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP1935417A1

  公开（公告）日：2008-06-25

  Disclosed is a composition for use in the prevention of a hypoglycemic condition, which comprises at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof as an active ingredient. The composition can promote the uptake of carbohydrate into brain cells to thereby prevent a hypoglycemic condition.

  本发明公开了一种用于预防低血糖症的组合物，该组合物包含至少一种选自支链氨基酸、其药学上可接受的盐及其衍生物的化合物作为活性成分。该组合物可以促进脑细胞对碳水化合物的吸收，从而预防低血糖症。
• ANTIDEPRESSANT AGENT
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP2077111A1

  公开（公告）日：2009-07-08

  An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof.

  一种抗抑郁剂，含有至少一种选自支链氨基酸、其药学上可接受的盐及其衍生物的化合物作为活性成分。
• THIAZIDEAMIDE DERIVATIVE AND USE THEREOF
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP3327010A1

  公开（公告）日：2018-05-30

  The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.

  本发明属于医药技术领域。具体而言，本发明涉及一种噻嗪酰胺衍生物化合物或其药学上可接受的盐或溶液，一种包含该化合物或其药学上可接受的盐或溶液的药物组合物，一种制备该化合物或其药学上可接受的盐或溶液的方法，以及该化合物或其药学上可接受的盐或溶液的用途。例如，根据本发明的化合物或其药学上可接受的盐或溶液可用于预防和/或治疗由物理创伤或相关疾病引起的神经退行性疾病或神经病理性疾病。
• Thiazideamide derivative and use thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：US10335417B2

  公开（公告）日：2019-07-02

  The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.

  本发明属于医药技术领域。具体而言，本发明涉及一种噻嗪酰胺衍生物化合物或其药学上可接受的盐或溶液，一种包含该化合物或其药学上可接受的盐或溶液的药物组合物，一种制备该化合物或其药学上可接受的盐或溶液的方法，以及该化合物或其药学上可接受的盐或溶液的用途。例如，根据本发明的化合物或其药学上可接受的盐或溶液可用于预防和/或治疗由物理创伤或相关疾病引起的神经退行性疾病或神经病理性疾病。